What is the latest market selling price of capmatinib in 2025?

Capmatinib is an important targeted therapy drug, mainly used to treat non-small cell lung cancer (NSCLC) carrying MET gene mutations. As a new type of small molecule kinase inhibitor, capmatinib prevents the growth and invasion of tumor cells by specifically inhibiting the MET pathway. It has shown good efficacy in clinical practice in recent years. In China, the original drug of capmatinib has been approved for marketing, which provides a new treatment option for many patients in need of targeted therapy.

Although capmatinib has been launched in China, its specific market price and medical insurance-related details have not yet been fully disclosed. It is understood that the domestic price of the original capmatinib in 200mg*60 tablets has exceeded RMB 30,000. This pricing reflects the high cost of new drug development and production to a certain extent. For many patients, this price will undoubtedly cause a financial burden, especially in the case of long-term medication, and how to pay for this cost has become a topic worthy of attention.

In overseas markets, the price of capmatinib is even more staggering. For example, in some European countries, the price of capmatinib’s original drug in 200mg*60 tablets may be as high as more than 50,000 yuan. Such prices not only put financial pressure on patients, but also pose challenges to the medical system. Although the price of drugs will be affected by factors such as exchange rate fluctuations, overall, capmatinib's positioning in the international market is still relatively high.

Faced with such high prices for original drugs, patients have begun to pay attention to whether there are alternative generic drugs on the market. At present, there are indeed some more affordable generics of capmatinib on the overseas market. The ingredients of these generic drugs are basically the same as the original drugs. For example, the generic capmatinib drug of 200mg*56 tablets produced by a pharmaceutical factory in Laos is priced at about more than 3,000 yuan, which is significantly lower than the price of the original drug.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib